VEGFA and neoplasm: Bevacizumab is a vascular endothelial growth factor A (VEGFA) monoclonal antibody that combines with VEGFA, attenuates VEGFA‐dependent tumor blood vessel formation, normalizes tumor blood vessels, prompts tumor cell apoptosis, inhibits tumor angiogenesis, and finally shrinks the tumor.20, 21